BenchSci

BenchSci is a global leader in AI solutions for preclinical R&D, focused on unraveling the complexities of biomedical research. Its ASCEND platform is designed to speed up drug discovery and complex research workflows across therapeutic areas, using proprietary evidence-based technology to tap into the collective history of biomedical experiments.

ASCEND includes:

• Comprehensive Data Foundation: Access to a large corpus of data including closed access papers, patents, preprints and third-party data.
• Scalable Enterprise-Grade Software: Handles workflows that have never been mapped before, so it can scale to large projects.
• Biology-Specific Multimodal AI: Biological Large Language Models (LLMs) that can understand experiments from text and figures, with scientific explainability and no hallucinations.
• Internal Data Integrations: Integrates internal pharma data across all therapeutic areas with enterprise-grade security and service.
• Science-First Approach: Scientific support and onboarding, with a team of over 100 scientists working alongside engineers and AI experts.

BenchSci's platform is geared for pharmaceutical and biotech R&D companies looking to accelerate and improve life-saving research. ASCEND's capabilities are designed to help address the leading cause of drug discovery project failures -- getting the biology wrong -- by providing a scalable AI assistant for preclinical organizations. Academic and non-profit institutions can use the platform for free, while pharma customers need a license to access the full range of features.

The use of Generative AI (GenAI) in the platform offers features like summarization and conversational AI, and BenchSci is committed to an ethical and responsible approach to AI adoption. Users can use ASCEND to inform their experiment decisions, decrease experimental failure, and guide the selection of various reagents.

BenchSci is dedicated to helping scientists accelerate drug discovery and ultimately improve patient outcomes. By bringing the latest advancements in AI to the drug discovery process, the company is working to exponentially accelerate the speed and quality of R&D.

Published on June 28, 2024